178
Participants
Start Date
December 7, 2023
Primary Completion Date
November 30, 2026
Study Completion Date
November 30, 2026
Atezolizumab
Atezolizumab will be given to participants either intravenously at a dosage of 1200mg or subcutaneously at a dosage of 1875 mg on Day 1 of each 21-day cycle for Arms A, B, and C, and on days 1 and 22 of concurrent chemoradiotherapy for Arm C only.
Tiragolumab
Tiragolumab will be given to participants intravenously at a dosage of 600 mg on day 1 of each 21-day cycle (Arms B and C), and on days 1 and 22 of concurrent chemoradiotherapy (Arm C only).
Hematology Oncology Associates of Central New York, P.C., East Syracuse
SUNY Upstate Medical University, Syracuse
Ohio State University, Columbus
University of Wisconsin, Madison
Rush University Medical Center, Chicago
Washington University Siteman Cancer Center, St Louis
Missouri Baptist Medical Center, St Louis
University of Nebraska Medical Center, Omaha
University of California San Diego Moores Cancer Center, La Jolla
Kaiser Permanente San Francisco Medical Center, San Francisco
Kaiser Permanente Vallejo Medical Center, Vallejo
Kaiser Permanente Oakland Medical Center, Oakland
Kaiser Permanente Santa Clara Medical Center, Santa Clara
Kaiser Permanente Roseville Medical Center, Roseville
New Hampshire Oncology - Hematology, PA, Manchester
Collaborators (1)
Genentech, Inc.
INDUSTRY
Alliance Foundation Trials, LLC.
OTHER